Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium)
Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium)
Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium)
Industry Day

Virtual Industry Day for Onshoring the Manufacturing of
Viral Hemorrhagic Fever Vaccine Candidates

Learn more about the recently released Draft Statement of Objectives for Onshoring the Manufacturing of Viral Hemorrhagic Fever Vaccine Candidates and gain valuable insights into the upcoming solicitation. Featured speakers include representatives from BARDA, International AIDS Vaccine Initiative, and Public Health Vaccines. This webinar is open to both BioMaP-Consortium members and non-members. Registration is required to attend.

When: Thurs., Aug. 28 from 1 to 4 p.m. ET
Sign Up Here
Draft SOO Option 2

Draft Statement of Objectives for Monoclonal Antibody Advanced Manufacturing Capability Improvement

The BioMaP-Consortium has released a Draft Statement of Objectives on behalf of BARDA to gather stakeholder feedback. Building on the demonstrated manufacturing performance of monoclonal antibodies (mAbs) for rapid response, the U.S. government aims to strengthen domestic preparedness against threats such as anthrax, Ebola, RSV, and SARS-CoV-2 by advancing technologies that improve the speed, efficiency, and resilience of mAb production. Feedback will be shared with the U.S. government to support planning and development efforts.

Responses Due: Sept. 1, 2025 at 11:59 p.m. ET
Learn More
AI Webinar

AI Advances & FDA Insights in
Pharmaceutical Manufacturing Webinar

Gain insights from three leaders driving innovation at the intersection of AI and pharmaceutical manufacturing. This webinar will cover cutting-edge technologies and innovations, real-world applications of AI in pharmaceutical manufacturing, key FDA insights, and partnership and collaboration opportunities.

When: Sept. 10, 2025 from 1 to 2 p.m. ET
Sign Up Here
previous arrow
next arrow

Get involved!

Seeking partnerships to rapidly respond to future Public Health Emergencies (PHE)

Member Benefits:

No Cost Barrier for Entry

Pre-negotiated Terms

Fast & Flexible Partnerships

Networking & Engagement with Industry

Industrial Base Expansion of Supply Chain

Engage with the network of organizations and personnel that provide all goods and services in support of the entire biomanufacturing process, to include, but not limited to, raw materials, consumables, and fill-finish services.

Biomanufacturing Capacity Expansion and Reservation

Prepare and provide timely, integrated, and sufficient medical countermeasures in response to emerging pathogens with pandemic potential through establishing, expanding and/or reserving drug substance and/or drug product manufacturing capacities.

Advanced Biomanufacturing Technologies

Address new and emerging technologies, that enhance existing capabilities that increase the speed, quality, safety, yield, efficiency of the biomanufacturing process or the safety, quality, effectiveness, or availability of the resulting biopharmaceutical drug product.